Purpose Of Review: The purpose of this review is to discuss the implications of personalized medicine for the treatment of hypertension, including resistant hypertension.
Recent Findings: We suggest a framework for the personalized treatment of hypertension based on the concept of a trade-off between simplicity and personalization. This framework is based on treatment strategies classified as low, medium, or high information burden personalization approaches. The extent to which a higher information burden is justified depends on the clinical scenario, particularly the ease with which the blood pressure can be controlled. A one-size-fits-many treatment strategy for hypertension is efficacious for most people; however, a more personalized approach could be useful in patients with subtypes of hypertension that do not respond as expected to treatment. Clinicians seeing patients with unusual hypertension phenotypes should be familiar with emerging trends in personalized treatment of hypertension.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594382 | PMC |
http://dx.doi.org/10.1007/s11906-019-0921-3 | DOI Listing |
Wiad Lek
January 2025
DEPARTMENT OF CLINICAL PHARMACY AND THERAPEUTICS, FACULTY OF PHARMACY, UNIVERSITY OF KUFA, KUFA, IRAQ.
Objective: Aim: This research aims to comprehensively assess the prescribing practices of anti-hypertensive medications in a sample of Iraqi patients with diabetes. Specifically, exploring medication types and classes, adherence to clinical guidelines for managing hypertension in the context of diabetes, and factors influencing prescribing decisions.
Patients And Methods: Materials and Methods: This descriptive cross-sectional retrospective study investigates medication usage in an outpatient clinic in Najaf, Iraq, utilizing systematic sampling.
PLoS One
January 2025
Department of Internal Medicine, University of Medicine and Pharmacy, Hue University, Hue, Vietnam.
Background: Medication adherence plays a crucial role in effectively managing hypertension, a significant public health concern, especially in regions like Central Vietnam. This study aimed to assess medication adherence levels among hypertensive patients in primary care settings and explore the factors influencing adherence within this specific population.
Methods: We conducted a cross-sectional study to evaluate medication adherence and its determinants among individuals with hypertension in Central Vietnam.
Ann Rheum Dis
January 2025
Department of Rheumatology, Université Paris Cité UFR de Médecine, Paris, France.
Objectives: To update the 2017 European Alliance of Associations for Rheumatology (EULAR) recommendations for treatment of systemic sclerosis (SSc), incorporating new evidence and therapies.
Methods: An international task force was convened in line with EULAR standard operating procedures. A nominal group technique exercise was performed in two rounds to define questions underpinning a subsequent systematic literature review.
Eur Heart J
January 2025
Center for Advanced Heart and Lung Disease and Baylor Heart and Vascular Institute, Baylor University Medical Center, 3410 Worth St, Ste 250, Dallas, TX 75226, USA.
Background And Aims: Recurrent myocardial infarction (MI) and incident heart failure (HF) are major post-MI complications. Herein, contemporary post-MI risks for recurrent MI and HF are described.
Methods: A total of 6804 patients with a primary discharge diagnosis of MI at 28 Baylor Scott & White Health hospitals (January 2015 to December 2021) were studied.
Int J Hematol
January 2025
Department of Blood Transfusion, Osaka University Hospital, Osaka, Japan.
Fostamatinib had superior efficacy to a placebo and acceptable safety profiles for at least 1 year in a phase 3 study of Japanese patients with primary immune thrombocytopenia. Here, we report the 3-year safety and efficacy of fostamatinib in that study. Data from 33 patients who received at least one dose of fostamatinib were analyzed.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!